Results 21 to 30 of about 17,034 (166)

Synergistic Effect of Cefazolin Plus Fosfomycin Against Staphylococcus aureus in vitro and in vivo in an Experimental Galleria mellonella Model

Frontiers in Pharmacology, 2021
Objectives: This study investigated the synergistic in vitro and in vivo activity of cefazolin plus fosfomycin against methicillin-susceptible and methicillin-resistant S.
Manuel Kussmann, Markus Obermueller, Matthias Karer, Matthias Karer, Richard Kriz, Rui-Yang Chen, Lena Hohl, Lisa Schneider, Heinz Burgmann, Ludwig Traby, Matthias G. Vossen   +10 more
doaj   +1 more source

Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence

Future Science OA, 2020
Aim: To evaluate the antibacterial activity of fosfomycin–meropenem and fosfomycin–colistin combinations against carbapenem-resistant Klebsiella pneumoniae (CR-Kp). Methods: A total of 50 CR-Kp isolates recovered from blood cultures were included in this
Yamuna Devi Bakthavatchalam, Abirami Shankar, Dhiviya Prabaa Muthuirulandi Sethuvel, Kalaiarasi Asokan, Kalaiarasi Kanthan, Balaji Veeraraghavan   +5 more
doaj   +1 more source

Prevalence of fosfomycin resistance and gene mutations in clinical isolates of methicillin-resistant Staphylococcus aureus

Antimicrobial Resistance and Infection Control, 2020
Background Fosfomycin exhibits excellent in vitro activity against multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Yi-Chien Lee, Pao-Yu Chen, Jann-Tay Wang, Shan-Chwen Chang   +3 more
doaj   +1 more source

Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study

Infectious Diseases and Therapy, 2020
Introduction Severe pneumonia caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) remains a difficult-to-treat infection. Considering the poor lung penetration of most antibiotics, the choice of the better antibiotic regimen is debated ...
Alessandro Russo, Matteo Bassetti, Valeria Bellelli, Luigi Bianchi, Federica Marincola Cattaneo, Stefania Mazzocchetti, Elena Paciacconi, Fabrizio Cottini, Arcangelo Schiattarella, Giuseppe Tufaro, Francesco Sabetta, Alessandro D’Avino   +11 more
doaj   +1 more source

Transporter Genes and fosA Associated With Fosfomycin Resistance in Carbapenem-Resistant Klebsiella pneumoniae

Frontiers in Microbiology, 2022
Infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) are of significant clinical concern worldwide. Fosfomycin is one of the limited treatment options for CRKP. However, resistance to fosfomycin in CRKP has been observed. In this study,
Yu-Ping Wang, Yu-Ping Wang, Yu-Ping Wang, Yen-Hao Chen, I-Cheng Hung, Po-Hsun Chu, Yu-Han Chang, Yi-Tsung Lin, Hung-Chih Yang, Hung-Chih Yang, Jin-Town Wang, Jin-Town Wang   +11 more
doaj   +1 more source

Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. [PDF]

PLoS ONE, 2010
BACKGROUND: Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal infections. A very convenient feature of fosfomycin, among others, is that although the expected frequency of resistant mutants is ...
Alexandro Rodríguez-Rojas, María D Maciá, Alejandro Couce, Cristina Gómez, Alfredo Castañeda-García, Antonio Oliver, Jesús Blázquez   +6 more
doaj   +1 more source

Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin–Resistant Enterococcus faecium in a Hollow Fiber Infection Model

Frontiers in Microbiology, 2021
The optimal therapy for severe infections caused by vancomycin-resistant Enterococcus faecium (VREfm) remains unclear, but the combination of linezolid and fosfomycin may be a good choice.
Shuaishuai Wang, Shuaishuai Wang, Huiping Liu, Huiping Liu, Jun Mao, Jun Mao, Yu Peng, Yu Peng, Yisong Yan, Yisong Yan, Yaowen Li, Yaowen Li, Na Zhang, Na Zhang, Lifang Jiang, Lifang Jiang, Yanyan Liu, Jiabin Li, Xiaohui Huang, Xiaohui Huang   +19 more
doaj   +1 more source

Prevalence of fosfomycin resistance and mutations in murA, glpT, and uhpT in methicillin-resistant Staphylococcus aureus strains isolated from blood and cerebrospinal fluid samples

Frontiers in Microbiology, 2016
In China, fosfomycin alone or in combination with other antibiotics is commonly used in the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Although fosfomycin-resistant S.
Zhuyingjie eFu, Ying eMa, Chunhui eChen, Yan eGuo, Fupin eHu, Yang eLiu, Xiaogang eXu, Minggui eWang   +7 more
doaj   +1 more source

High incidence of fosfomycin-resistant uropathogenic E. coli among children

BMC Infectious Diseases, 2023
Background There are few epidemiological or molecular data on Escherichia coli (E. coli) strains resistant to fosfomycin. In this study, we described the occurrence and characterization of fosfomycin-resistant uropathogenic E.
Wedad M. Abdelraheem, W. K.M Mahdi, Ibtehal S. Abuelela, Noha Anwar Hassuna   +3 more
doaj   +1 more source

Plasma and Urine Pharmacokinetics of Oral Fosfomycin Tromethamine in Dogs

Veterinary Sciences, 2023
Fosfomycin is a broad-spectrum, bactericidal antibiotic with low toxicity. It has been used in human medicine and is a promising candidate for treating infections in veterinary medicine.
Nattha Jariyapamornkoon, Koranis Patthanachai, Nipattra Suanpairintr   +2 more
doaj   +1 more source